Skip to search formSkip to main contentSkip to account menu

selinexor

An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

KPT-330
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Selinexor: First Global Approval
Selinexor (XPOVIO™) is a first-in-class, oral, small molecule Exportin-1 (XPO1) inhibitor that is being developed by Karyopharm… 
Review
2019
Review
2019
Inhibitors of nuclear transport.
Highly Cited
2018
Highly Cited
2018
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through… 
Highly Cited
2018
Highly Cited
2018
Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma… 
Highly Cited
2018
Highly Cited
2018
Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
Exportin-1 (XPO1) controls the nucleo-cytoplasmic trafficking of several key growth regulatory and tumor suppressor proteins… 
Highly Cited
2017
Highly Cited
2017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.
Selinexor is a novel, first-in-class, selective inhibitor of nuclear export compound, which blocks exportin 1 (XPO1) function… 
Highly Cited
2017
Highly Cited
2017
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We… 
Highly Cited
2016
Highly Cited
2016
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.
Purpose This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a novel, oral… 
Highly Cited
2016
Highly Cited
2016
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity… 
Highly Cited
2015
Highly Cited
2015
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses are infrequent, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)